eukaryotic translation initiation factor 3 subunit L pseudogene 3Genealiases: []
Q-omics provides the consensus-scored EIF3LP3 profile across patient tissues and cancer cell-line models. EIF3LP3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, EIF3LP3 is differentially expressed in 6, with the highest sampling consensus in COAD. Additionally, EIF3LP3 RNA expression shows 15,520 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight HNSC, COAD, and TGCT as cancer lineages where EIF3LP3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EIF3LP3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EIF3LP3 survival associations across molecular data types. EIF3LP3 RNA expression shows survival associations in the most cancer types (24). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EIF3LP3 RNA expression–survival associations across cancer types. High EIF3LP3 expression shows unfavorable associations in HNSC, but favorable associations in MESO, UCS, LGG, CHOL and LAML. The HNSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for EIF3LP3 RNA expression.
This table summarizes EIF3LP3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for EIF3LP3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EIF3LP3 shows lower tumor expression in THCA and LUSC and higher tumor expression in COAD, LIHC, CHOL and KIRC. The COAD box plot shows higher EIF3LP3 RNA expression in tumor versus normal tissue (log2 FC = +0.208, t-test p = .005).
This table shows molecular features associated with EIF3LP3 in patient tissues and cancer cell lines. In patient samples, EIF3LP3 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set.
